Awareness is necessary to prevent obesity, because it causes many diseases. Now a pharmaceutical company has launched its medicine in India to prevent obesity. This is a special injection, about which the company claims that it controls obesity rapidly. Let's know the whole thing in detail.

Recently, during the 'Mann Ki Baat' program, Prime Minister Narendra Modi had emphasized on awareness for obesity prevention. The PM appealed to people to exercise and said that the use of oil in food should be reduced by 10 percent. Now a pharmaceutical company working for a long time to prevent obesity has launched a drug in India, which is claimed to be the first treatment of its kind for obesity, overweight and type-2 diabetes. It activates both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon Like Peptide-1) hormone receptors.

After a long wait, American pharmaceutical company Eli Lilly has now launched a drug called Monzaro (Tirzepatide) for the prevention of diabetes and obesity in India. Its 2.5 mg vial has been priced at Rs 3500 and 5 mg vial at Rs 4375. This drug, which is usually taken once a week, will cost between Rs 14000 and Rs 17500 per month depending on the dosage prescribed by doctors. This drug has been launched in a single dose vial after getting marketing authorization from CDSCO.

Weight is reduced rapidly

The company says that when this drug was tested, it was found that adults taking Monjaro along with diet and exercise lost an average of 21.8 kg at the highest dose (15 mg) and 15.4 kg at the lowest dose (5 mg) over 72 weeks in a controlled clinical trial. Lilly India President and General Manager Winslow Tucker said that the double burden of obesity and type 2 diabetes in India is rapidly emerging as a major public health challenge. Lilly is committed to collaborating with the government and industries to raise awareness about these diseases, improve prevention and management.

10 crore people in India suffer from diabetes

According to medical studies, more than 10 crore people in India suffer from diabetes, out of which about half get inadequate treatment and their glycemic control is also not proper. Obesity is a chronic disease that is a major risk factor for diabetes and causes more than 200 diseases including hypertension, dyslipidemia, coronary heart disease and obstructive sleep apnea. By 2023, the prevalence of adult obesity in India is estimated to be around 6.5 per cent, affecting more than 20 crore people.